GLP‐1 based therapies: differential effects on fasting and postprandial glucose
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1), a gut‐derived hormone secreted in response to nutrients, has several glucose and weight regulating actions including enhancement of glucose‐stimulated insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and reduction in food intake. Because of these multiple effects, the GLP‐1 receptor system has become an attractive target for type 2 diabetes therapies. However, GLP‐1 has significant limitations as a therapeutic due to its rapid degradation (plasma half‐life of 1–2 min) by dipeptidyl peptidase‐4 (DPP‐4). Two main classes of GLP‐1‐mediated therapies are now in use: DPP‐4 inhibitors that reduce the degradation of GLP‐1 and DPP‐4‐resistant GLP‐1 receptor (GLP‐1R) agonists. The GLP‐1R agonists can be further divided into short‐ and long‐acting formulations which have differential effects on their mechanisms of action, ultimately resulting in differential effects on their fasting and postprandial glucose lowering potential. This review summarizes the similarities and differences among DPP‐4 inhibitors, short‐acting GLP‐1R agonists and long‐acting GLP‐1R agonists. We propose that these different GLP‐1‐mediated therapies are all necessary tools for the treatment of type 2 diabetes and that the choice of which one to use should depend on the specific needs of the patient. This is analogous to the current use of modern insulins, as short‐, intermediate‐ and long‐acting versions are all used to optimize the 24‐h plasma glucose profile as needed. Given that GLP‐1‐mediated therapies have advantages over insulins in terms of hypoglycaemic risk and weight gain, optimized use of these compounds could represent a significant paradigm shift for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“Although the potency of liraglutide is reduced 100-fold relative to GLP-1 (albumin binding is 98–99%), it retains the basic actions of GLP-1 [2].”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“9 mmol/mol) compared to placebo when added to metformin [69], a sulfonylurea (SFU) [70] or a combination of metformin and a SFU [71].”
BackgroundSelf-citationBuse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 2×
“In addition, long-acting GLP-1 agonists may have less nausea than observed with short-acting GLP-1 agonists [76, 91].”
BackgroundMonnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 2×
“demonstrated that fasting hyperglycaemia is the major contributor to HbA1c in poorly controlled subjects, while postprandial hyperglycaemia is the major contributor to HbA1c in subjects nearing target goals [1].”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“While both chronic infusions and bolus injections of GLP-1 are associated with weight loss [31, 33], administration of DPP-4 inhibitors typically results in weight neutrality [8, 51–53].”
BackgroundKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationNauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 5×
“Interestingly, there appears to be tachyphylaxis of nausea (the most common side effect) with chronic exenatide BID treatment without a loss of effect on gastric emptying or PPG [69–71, 78] and less nausea is observed with exenatide once weekly than with exenatide BID despite higher plasma concentrations [76].”
BackgroundInfluentialGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“4 mmol/l [83–87].”
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“described increased reports of pancreatic cancer with exenatide and sitagliptin usage in the FDA AERS (Adverse Event Reporting System) database compared to other diabetes therapies [113].”
ResultThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · cited 1×
“4 mmol/l [83–87].”
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · cited 1×
“4 mmol/l [83–87].”
Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“Following food ingestion, GLP-1 appears in the plasma within minutes and due to its rapid degradation by dipeptidyl peptidase-4 (DPP-4), is undetectable by 3 h [5–7].”
BackgroundBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Nauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“GLP-1 enhances insulin secretion in a glucose-dependent manner [20], augmenting both the first and second phase of secretion [21].”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“Although data are limited, existing results suggest that this combination could be a promising therapy to treat both fasting and postprandial hyperglycaemia with accompanied weight loss and no increase in hypoglycaemia [125].”
BackgroundWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · cited 1×
“GLP-1 is thought to play an important physiological role to regulate plasma glucose in the postprandial period through several mechanisms of action: enhancement of glucosestimulated insulin secretion, suppression of glucagon secretion and slowing of gastric emptying [13–19].”
BackgroundBlevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448 · cited 1×
“The short and long-acting exenatide formulations were directly compared in two studies of 26-week [74] and 30-week [76] duration.”
BackgroundYoung, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · cited 1×
“8 mmol/mol) [73–76] with more substantial improvements in FPG than had been observed in the exenatide BID studies.”
BackgroundSelf-citationGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · cited 1×
“Although the exact mechanisms by which GLP-1 regulates gastric function are unknown, it is clear that vagal afferents are important [23, 24].”
BackgroundDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“that demonstrated a reduced gastric emptying and PPG effect at the lunch meal compared to the breakfast meal during a continuous intravenous infusion of native GLP-1 [77].”
BackgroundBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Self-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“Lastly, GLP-1 appears to play a role in mealtime satiety signalling, which could impact plasma glucose through a reduction in caloric load ingestion, leading to reductions in bodyweight [13, 19, 33, 34].”
BackgroundDeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802418851 · Cited by 373
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Drucker, D. J., Sherman, S. I., Gorelick, F. S., Bergenstal, R. M., Sherwin, R. S., & Buse, J. B. (2010) · Diabetes Care · doi:10.2337/dc09-1499 · Cited by 316
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 1×
“While DPP-4 inhibitors have a small effect on PPG, the majority of the HbA1c lowering effect results from reductions in FPG [45, 47, 48].”
BackgroundFehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297 · cited 1×
“Like GLP-1, exenatide slows gastric emptying [60], suppresses glucagon [61, 62] and enhances first- and second-phase glucose-stimulated insulin secretion, as well as insulin secretion in response to a combined glucose and arginine stimulus [63–65].”
BackgroundSelf-citationHare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 1×
“Like GLP-1, exenatide slows gastric emptying [60], suppresses glucagon [61, 62] and enhances first- and second-phase glucose-stimulated insulin secretion, as well as insulin secretion in response to a combined glucose and arginine stimulus [63–65].”
BackgroundSelf-citationHegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“In addition, plasma concentrations of calcitonin were not altered in over 5000 subjects in liraglutide clinical trials [111].”
BackgroundWettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153
Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132 · cited 1×
“Treatment for 1 year with exenatide BID improved β-cell function compared to insulin glargine with similar overall reductions in HbA1c [68].”
BackgroundSelf-citationBarrington, P., Chien, J. Y., Showalter, H. D. H., Schneck, K., Cui, S., Tibaldi, F., Ellis, B., & Hardy, T. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01364.x · Cited by 120
Quddusi, S., Vahl, T. P., Hanson, K., Prigeon, R. L., & D’Alessio, D. A. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.791 · Cited by 111 · cited 1×
“GLP-1 enhances insulin secretion in a glucose-dependent manner [20], augmenting both the first and second phase of secretion [21].”
BackgroundFlint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69 · cited 3×
“For GLP-1R agonists, gastrointestinal adverse events are common, dose-dependent, transient, and can be reduced through dose-titration strategies in most cases [96].”
BackgroundInfluential
Cited by
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“currently under advanced clinical development (Fineman et al. 2012), but the preliminary clinical data are beyond the scope of this review.”
InfluentialSelf-citationReview of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Madsbad, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12596 · Cited by 305
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Cornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
He, Z., Gao, Y., Lieu, L., Afrin, S., Cao, J., Michael, N. J., Dong, Y., Sun, J., Guo, H., & Williams, K. W. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.008 · Cited by 128
Metadata
- Authors
- Fineman, M. S., Cirincione, B. B., Maggs, D., & Diamant, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-02-13
- Volume
- 14
- Issue
- 8
- Pages
- 675-688
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2116286254
- Cited by
- 113
- References
- 48
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.